In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
 EMAIL TO FRIEND     |      PRINTER FRIENDLY     |    
          advertisement

Race Not a Factor if Breast Cancer Chemo Succeeds

Oct. 14 (HealthDay News) -- Among women with locally advanced breast cancer who undergo the same class of chemotherapy, race doesn't affect the odds of having no sign of disease at surgery, a new study finds.

Having no sign of the disease is considered a good sign that bodes well for a woman's prognosis, although it's not a guarantee that the cancer has vanished for good, the study authors noted.

"Our findings confirm [that having no sign of the disease] is a strong prognostic indicator and a surrogate for good survival, despite a patient's race, and that it's vital we continue to strive towards achieving this milestone for all women with breast cancer," said study co-author Dr. Mariana Chavez-MacGregor, a medical oncology fellow at the University of Texas M.D. Anderson Cancer Center. "The study also mandates that we continue to research the differences across races in breast cancer."

Researchers know that there are racial disparities when it comes to breast cancer. While black women are less likely to develop breast cancer than white women, their death rate is 37 percent higher. The death rate is also increased in Hispanic women, studies have found.

It is unclear why the disparities exist, and researchers continue to try to determine whether it has something to do with access to health care and screening or variations in the tumors between women of different races.

The new study by Chavez-MacGregor and colleagues at the University of Texas M.D. Anderson Cancer included 2,074 patients diagnosed and treated for stage II and III breast cancer. The average age of the women was 50, and they all received neoadjuvant anthracycline- and taxane-based chemotherapy.

According to the researchers, who were to report their findings at the 2009 Breast Cancer Symposium held Oct. 8 to 10 in San Francisco, there was no statistical difference in the percentages of patients who reached what is known as "pathological complete response." The rate was 12.3 percent in white patients, 12.5 percent in black patients, 14.2 percent in Hispanic patients and 11.5 percent in patients of other races.

Overall survival rates for five years were 79 percent in whites, 57 percent in blacks, 79 percent in Hispanics and 84 percent in other races, the study authors noted.


SOURCE: University of Texas M.D. Anderson Cancer Center, news release, Oct. 14, 2009

advertisement

Advice from Dr. Nancy Snyderman

Dr. Nancy Snyderman

Helpful tips and information on weight loss

Get answers from an expert
advertisement

YourTotalHealth      

Home  |  Health Centers  |  Health A-Z  |  Staying Healthy  |  Diet & Fitness  |  Woman & Family  |  Pregnancy  |  Community  |  

also on iVillage: Pregnancy & Parenting  |  Beauty & Style  |  Home & Garden  |  Food  |  Weddings  |  Love  |  Entertainment  |  NeverSayDiet

Terms of Service  |  Privacy Policy  |  Site Map  |  Newsletters  |  Feedback

Copyright (c) 2000-2009 iVillage Inc. All rights reserved. The information provided on this site is intended for your general knowledge only and is not a substitute for professional medical advice or treatment for specific medical conditions. You should not use this information to diagnose or treat a health problem or disease without consulting with a qualified healthcare provider. Please consult your healthcare provider with any questions or concerns you may have regarding your condition.